Emerging from a cloud of regulatory questions and mixed clinical results, Caplyta (generic lumateperone) an atypical antipsychotic from Intra-Cellular Therapies, Inc. was given FDA approval 20 December 2019, and is now being heavily marketed. There are over a dozen of these second-generation antipsychotics, with varying activity at the brain receptors for various neurotransmitters.
It is hardly clear whether lumateperone has any advantages over other antipsychotic drugs. The primary reason for researching and releasing another atypical antipsychotic is to try to reduce the side effects, rather than to actually eliminate the symptoms, since no one really knows what causes these symptoms. The manipulation of neurotransmitters in the brain is just a guess, unfounded by any real understanding, just as the actual causes of so-called schizophrenia (psychiatry’s “For Profit Disease”) are not understood.
Side Effects of this dangerous drug include: stroke, neuroleptic malignant syndrome, tardive dyskinesia, diabetes, low white blood cell count, low blood pressure, falls, seizures, sleepiness, trouble concentrating, high temperature, difficulty swallowing, withdrawal symptoms in newborn babies exposed to Caplyta during the third trimester, pruritus (itchy skin), rash, urticaria (hives), increased mortality in elderly patients with dementia-related psychosis.
Patients are urged to avoid Cytochrome P450 (CYP3A4) inducers or inhibitors, since these may exacerbate the adverse reactions, causing violence and suicide.
List Price: $44 per 42mg capsule, with a peak sales estimate of $60 million in 2020 and $400 million by 2024. There may be conditions for insurance approval; for example, UnitedHealthcare may require the failure, contraindication, or intolerance to three other atypical antipsychotics before giving approval to pay for the use of Caplyta.
The antipsychotic activity of Caplyta is thought to be mediated through a combination of antagonism of serotonin receptors and antagonism of dopamine receptors in the brain, however the actual mechanism of action of Caplyta in schizophrenia is unknown.
Clinical trial results were measured by the opinion of a clinician observing or asking the patient about their feelings. The results require cautious interpretation and could represent chance findings. One phase III trial showed some symptomatic improvement and another phase III trial failed to show any improvement over placebo.
Obviously use this drug at your own serious risk, and insist on Full Informed Consent.
The real problem is that psychiatrists fraudulently diagnose life’s problems as an “illness”, and stigmatize unwanted behavior as “diseases.” Psychiatry’s stigmatizing labels, programs and treatments are harmful junk science; their diagnoses of “mental disorders” are a hoax – unscientific, fraudulent and harmful. All psychiatric treatments, not just psychiatric drugs, are dangerous.
It is vital that patients watch the video documentary “Making A Killing – The Untold Story of Psychotropic Drugging“. Containing more than 175 interviews with lawyers, mental health experts, the families of psychiatric abuse victims and the survivors themselves, this riveting documentary rips the mask off psychotropic drugging and exposes a brutal but well-entrenched money-making machine. The facts are hard to believe, but fatal to ignore.
